Line 717: | Line 717: | ||
<br> | <br> | ||
<h4><u>BioBricks PCR amplification</u></h4> | <h4><u>BioBricks PCR amplification</u></h4> | ||
− | <img src="https://static.igem.org/mediawiki/2018/4/4a/T--NYU_Abu_Dhabi--Parts4.png"width="300" class=" | + | <img src="https://static.igem.org/mediawiki/2018/4/4a/T--NYU_Abu_Dhabi--Parts4.png"width="300" class="center2"> |
<br> | <br> | ||
<h2><i>Figure 1: Agarose gel electrophoresis showing PCR amplification of: gbpA BioBrick <a href="http://parts.igem.org/Part:BBa_K2808000"target="_blank">BBA_K2808000</a>; hipO <a href="http://parts.igem.org/Part:BBa_K2808001"target="_blank">BBA_K2808001</a>; invA <a href="http://parts.igem.org/Part:BBa_K2808002"target="_blank">BBA_K2808002</a>; lmo0733 <a href="http://parts.igem.org/Part:BBa_K2808003"target="_blank">BBA_K2808003</a>. (Lane 1) 500 bp DNA ladder (Bio-Rad); (Lane 2) gbpA BioBrick; (Lane 3) negative control for gbpA BioBrick; (Lane 4) hipO BioBrick; (Lane 5) negative control for hipO BioBrick; (Lane 6) invA BioBrick; (Lane 7) negative control for invA BioBrick; (Lane 8) lmo0733 BioBrick; (Lane 9) negative control for lmo0733 BioBrick. Lanes 2, 4, 6, and 8 show bands around 1019 bp, 203 bp, 818 bp, and 403 bp respectively as expected for the PCR products of the gbpA, hipO, invA, and lmo0733 BioBricks respectively. | <h2><i>Figure 1: Agarose gel electrophoresis showing PCR amplification of: gbpA BioBrick <a href="http://parts.igem.org/Part:BBa_K2808000"target="_blank">BBA_K2808000</a>; hipO <a href="http://parts.igem.org/Part:BBa_K2808001"target="_blank">BBA_K2808001</a>; invA <a href="http://parts.igem.org/Part:BBa_K2808002"target="_blank">BBA_K2808002</a>; lmo0733 <a href="http://parts.igem.org/Part:BBa_K2808003"target="_blank">BBA_K2808003</a>. (Lane 1) 500 bp DNA ladder (Bio-Rad); (Lane 2) gbpA BioBrick; (Lane 3) negative control for gbpA BioBrick; (Lane 4) hipO BioBrick; (Lane 5) negative control for hipO BioBrick; (Lane 6) invA BioBrick; (Lane 7) negative control for invA BioBrick; (Lane 8) lmo0733 BioBrick; (Lane 9) negative control for lmo0733 BioBrick. Lanes 2, 4, 6, and 8 show bands around 1019 bp, 203 bp, 818 bp, and 403 bp respectively as expected for the PCR products of the gbpA, hipO, invA, and lmo0733 BioBricks respectively. | ||
Line 729: | Line 729: | ||
<h2>The 2017 team worked on a portable device that could identify Shiga Toxin producing E.Coli over 30 minutes. This device utilised LAMP for amplification and the reaction took place in a gel with wells. The issues with this device are as follows: | <h2>The 2017 team worked on a portable device that could identify Shiga Toxin producing E.Coli over 30 minutes. This device utilised LAMP for amplification and the reaction took place in a gel with wells. The issues with this device are as follows: | ||
</h2> | </h2> | ||
− | |||
<h2>1. <b>User Interaction: </b>The user was required to mix the food sample in a test tube and pipette it into each well separately. It can be noticed that this device was not user friendly as the target group were roadside food vendors. Most food vendors will not have the time or knowledge to use a pipette to check the food before serving it. | <h2>1. <b>User Interaction: </b>The user was required to mix the food sample in a test tube and pipette it into each well separately. It can be noticed that this device was not user friendly as the target group were roadside food vendors. Most food vendors will not have the time or knowledge to use a pipette to check the food before serving it. | ||
</h2> | </h2> | ||
Line 740: | Line 739: | ||
<h2>While our team was brainstorming for new project ideas, we noticed these issues in EcoLamp and considered the option of improving it. This thought was further strengthened by our interaction with potential target customers and users. The team took each aspect from the above observations and improved them in the following ways: | <h2>While our team was brainstorming for new project ideas, we noticed these issues in EcoLamp and considered the option of improving it. This thought was further strengthened by our interaction with potential target customers and users. The team took each aspect from the above observations and improved them in the following ways: | ||
</h2> | </h2> | ||
− | |||
<h2>1. <b>User Interaction: </b>The team worked on developing a hardware component that will include all the processes of sample collection and processing into one device. This meant replacing the test tube, cotton swab and pipette with one device, which was also contamination free and does not leak. The team after multiple tests, developed the sample collector which uses the ‘swab and press’ mechanism for sample collection. The sample is then added to the testing unit (chip) by the lid with a dripper. These additions simplify the numerous processes, thus making it suitable for any user with any background.</h2> | <h2>1. <b>User Interaction: </b>The team worked on developing a hardware component that will include all the processes of sample collection and processing into one device. This meant replacing the test tube, cotton swab and pipette with one device, which was also contamination free and does not leak. The team after multiple tests, developed the sample collector which uses the ‘swab and press’ mechanism for sample collection. The sample is then added to the testing unit (chip) by the lid with a dripper. These additions simplify the numerous processes, thus making it suitable for any user with any background.</h2> | ||
<h2>2. <b>Variety of Pathogens: </b>The biologists in the team worked hard and developed the existing protocol to suit multiplexing, which can be used in other devices made by Pathogene in the future. The team also worked on primers for four different pathogens which has enabled us to develop a device that can test for four different pathogens with one sample. </h2> | <h2>2. <b>Variety of Pathogens: </b>The biologists in the team worked hard and developed the existing protocol to suit multiplexing, which can be used in other devices made by Pathogene in the future. The team also worked on primers for four different pathogens which has enabled us to develop a device that can test for four different pathogens with one sample. </h2> |
Revision as of 16:13, 13 October 2018
<!DOCTYPE html>